Osteoarthritis today: Lost in translation?

Area of Science:

• Orthopedics
• Rheumatology
• Pharmacology

Background:

• Osteoarthritis (OA) is a prevalent joint disease causing pain, functional loss, and significant economic burden.
• Current OA therapies provide only moderate symptom relief and lack disease-modifying capabilities.
• Drug development for OA is hindered by late diagnosis, disease heterogeneity, and a lack of validated biomarkers.

Purpose of the Study:

• To review the current landscape of osteoarthritis (OA).
• To summarize emerging therapies and potential biomarkers for OA treatment.
• To outline current OA treatment guidelines, focusing on knee OA.

Main Methods:

• Literature review of OA therapies in development.
• Analysis of potential biomarkers undergoing evaluation.
• Summary of existing OA treatment guidelines.

Main Results:

• Identified limitations in current OA therapeutic options.
• Highlighted challenges in OA drug development, including heterogeneity and biomarker scarcity.
• Presented an overview of ongoing research and established treatment protocols for knee OA.

Conclusions:

• There is a critical need for disease-modifying OA treatments.
• Advancements in biomarker identification and outcome measures are crucial for future OA drug development.
• Current guidelines emphasize symptom management, but novel approaches are required for effective OA intervention.